Skip to main content
NCBI home page
ACS Omega logoLink to ACS Omega
. 2020 Mar 10;5(11):6163–6168. doi: 10.1021/acsomega.0c00188

Synthesis and Antibacterial Activities of Different Five-Membered Heterocyclic Rings Incorporated with Pyridothienopyrimidine

Mohamed Ge Zayda †,‡,*, Adel A-H Abdel-Rahman ‡, Farag A El-Essawy §,‡
PMCID: PMC7098019  PMID: 32226900

Abstract

graphic file with name ao0c00188_0003.jpg

Certain pyridothienopyrimidine derivatives exhibit antiatheroscleorotic, antibacterial, antiviral, antidepressant, antidiabetic, antihypertensive, anticancer, antihistaminic, antiallergic, anti-inflammatory, spasmolytic, analgesic, and neurotropic activities. 4-Hydrazino-7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine (1) is a reported pyridothienopyrimidine derivative. In the current study, (1) has been reacted with different reagents to obtain 12 new pyridothienopyrimidine derivatives. The newly synthesized five-membered heterocyclic rings incorporated with pyridothienopyrimidines have been screened for their antibacterial activities. The results encourage further studies on other possible biological activities.

Introduction

As an example of a triheterocyclic system, pyridothienopyrimidine has interesting biological activities among its derivatives which have attracted much attention. Pyridothienopyrimidines are a special class of thienopyridine derivatives. There are two regioisomeric structures, namely, 5H-thieno[2,3,4-e,d]pyrido[4,3-d]pyrimidine (Figure 1A) or pyrido[3′,2′:4,5] thieno[3,2-d]pyrimidine (Figure 1B). These two structures give all pyridothienopyrimidine derivatives which are prepared by annulation of thieno[2,3-b] pyridines.1

Figure 1.

Figure 1

Open in a new tab

Chemical structures of 5H-thieno[2,3,4-e,d]pyrido[4,3-d]pyrmidine (A) and pyrido[3′,2′:4,5] thieno[3,2-d]pyrimidine (B).

Among all fused thienoazines, pyridothienopyrimidine derivatives have been studied the most. These derivatives act as bactericides2−6 fungicides,2−6 antiprotozoals,7 or immunomodulators; exhibit antianaphylactic, antiallergic,8 anticonvulsive,9 analgetic, or anti-inflammatory activities;10,11 and are used as intermediate products in chemical pharmaceutical industry.1

In addition to antimicrobial,2−6 anticonvulsant,9 and anticancer activities12−17 of pyridothienopyrimidine derivatives, recent studies showed that they have the ability to specifically activate testicular steroidogenesis without affecting thyroid functions.18 They also have inhibitory effects on some closely linked factors to human malignancies such as cellular mesenchymal–epithelial transition factor;19 the Moloney murine leukemia virus-1 (pim-1)20 proviral integration site; some signaling pathways that play an important role in tumorigenesis;21 VEGFR-2 receptors to reduce angiogenesis or lymphangiogenesis;22 and act as alpha-1 blockers23 that are mainly used as a prescribed drugs for benign prostatic hyperplasia, manage hypertension, and treatment of posttraumatic stress disorder.

Within this respect, the current study has aimed to examine the chemistry of 4-hydrazino-7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine24 to be used as a starting material for the synthesis of some new pyrazole, pyrazolopyrimidine, and thiazole derivatives and investigate their antibacterial activities.

Results and Discussion

Ethoxymethylene malononitrile and 4-hydrazino-7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine (1) were refluxed in absolute ethanol to give 5-amino-1-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazole-4-carbonitrile (2) in 58% yield. Nitrile derivative (2) was refluxed in 80% formic acid and/or acetic acid to afford 1-(7,9-dimethylpyrido[3′,2′:4,5] thieno[3,2-d]pyrimidin-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (3) and 1-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-6-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (4), respectively. A mixture of ethoxymethylene cyanoactate and (1) was refluxed in absolute ethanol to give 2-(7,9-dimethylpyrido [3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonitrile (5) in 72% yield. Acid hydrolysis occurred for (5) which was refluxed in 10% sulfuric acid to give 2-(7,9-dimethylpyrido [3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic acid (6) in 41% yield. Diethyl ethoxymethylenemalonate and (1) were refluxed in absolute ethanol to obtain a powder of ethyl 2-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate (7) in 95% yield. Hydrazinolysis of (7) gave a powder of 2-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carbohydrazide (8) in 53% yield. Treatment of (1) with phenyl isothiocyanate afforded a solid product of 2-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-N-phenylhydrazinecarbothioamide (9) in 58% yield. A mixture of anhydrous sodium acetate in absolute ethanol was prepared to obtain (9), and finally phenacyl bromide and/or ethylbromoacetate were/was added to get a solid product of (2E)-3,4-diphenyl-1,3-thiazol-2(3H)-one (7,9-dimethylpyrido [3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)hydrazone (10) in 71% yield and (2E)-3-phenyl-1,3-thiazolidine-2,4-dione 2-[(7,9-dimethylpyrido [3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)hydrazone] (11) in 71% yield. A mixture of acetylacetone and/or ethylacetoacetate and (1) was refluxed in absolute ethanol to give 4-(3,5-dimethyl-1H-pyrazol-1-yl)-7,9-dimethylpyrido[3′,2′:4,5]thieno [3,2-d]pyrimidine (12) in 78% yield and 2-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (13) in 84% yield. The structures of (2–13) were established by infrared (IR) as well as proton nuclear magnetic resonance (1H NMR) spectra. All reactions are illustrated in Scheme 1. Physical properties and structural data for the newly synthesized pyridothienopyrimidine derivatives are shown in Table 1.

Scheme 1. Synthesis of New Pyridothienopyrimidine Derivatives.

Scheme 1

Open in a new tab

Table 1. Physical Properties and Structural Data for the Synthesized Compounds.

comp. no. mp (°C) yield (%) mol. formula MW (g/mol)
2 127–129 58 C15H11N7S 321.36
3 213–215 55 C16H11N7SO 349.37
4 228–231 45 C17H13N7SO 363.40
5 220–222 72 C15H10N6SO 322.34
6 271–273 41 C15H11N5SO3 341.34
7 203–205 95 C17H15N5SO3 369.40
8 191–193 53 C15H13N7SO2 355.37
9 181–183 58 C18H16N6S2 380.49
10 207–209 71 C26H20N6S2 480.61
11 181–183 71 C20H16N6S2O 420.51
12 219–221 78 C16H15N5S 309.39
13 237–239 84 C15H12N5SO 310.35
Open in a new tab

A screening for antibacterial activities of the newly synthesized pyridothienopyrimidine derivatives has been performed against three microorganisms (Table 2).

Table 2. MIC (in μg/mL) of the Title Compoundsa.

comp. B. subtilis (Gram +ve) P. aeruginosa (Gram −ve) Streptomyces species (actinomycetes)
penicillin 31 46 33
2 100 125 b
3 100 100 250
4 100 250 75
5   75 75
6 75 125 100
7 75 100 75
8 75 100 75
9 125 500 250
10 250   125
11 75   125
12 125 125 500
13 250 125  
Open in a new tab
a

The negative control DMSO showed no activity.

b

Totally inactive (MIC > 500 μg/mL).

Materials and Methods

Synthetic Methods, Analytical and Spectral Data

A Büchi melting point apparatus was used to measure the newly synthesized pyridothienopyrimidine derivatives’ melting points, which were uncorrected. A Bruker-Vector22 spectrometer (Bruker, Bremen, Germany) was used to record IR spectra (KBr). A Varian Gemini spectrometer (300 MHz, DMSO-d6) was used to record 1H NMR with tetramethylsilane (TMS) as an internal reference. The chemical shifts are expressed in δ scale (ppm) relative to TMS as a reference, and the coupling constants (J values) are given in hertz (Hz). Analytical thin layer chromatography was performed to monitor the progress of the reactions using aluminum silica gel 60 F245 plates (Merck, Darmstadt, Germany). Antimicrobial activities were screened at the College of Medicine, Dar Al Uloom University, Riyadh, Kingdom of Saudi Arabia.

Experimental Section

5-Amino-1-(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-1H-pyrazole-4-carbonitrile (2)

A mixture of ethoxymethylene malononitrile (0.55 g, 4 mmol) and 4-hydrazino-7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol (30 mL) for 10 h. The resulting precipitate was filtered off with suction, washed with ethanol, and recrystallized from ethanol to give a colored powder of (2) (58%), mp 127–129 °C. IR (KBr) ν cm–1: 3350–3280 (NH2), 1940, 1888 (CH aliphatic), 2230 (C≡N) cm–1. 1H NMR (DMSO-d6) δ in ppm: 2.49, 2.60 (2s, 6H, 2CH3), 4.72 (br s, 2H, NH2), 7.32 (s, 1H, Ar-H), 8.15 (s, 1H, Ar-H), 9.11 (s, 1H, Ar-H).

1-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (3)

Nitrile derivative (2) (0.31 g, 1 mmol) was refluxed in 80% formic acid (10 mL) for 11 h and then poured on cold water. The solid product of (3) (55%) was collected after filtration with suction and recrystallized from ethanol, mp 213–215 °C. IR (KBr) ν cm–1: 2920, 2890 (CH aliphatic), 1680 (C=O), 3200 (NH). 1H NMR (DMSO-d6) δ in ppm: 2.48, 2.56 (2s, 6H, 2CH3), 7.00 (s, 1H, Ar-H), 7.28 (s, 1H, Ar-H), 8.97 (s, 1H, Ar-H), 9.25 (br s, 1H, NH).

1-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-6-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (4)

Nitrile derivative (2) (0.31 g, 1 mmol) was refluxed in 80% acetic acid (10 mL) and HCl (0.5 mL) for 10 h and then poured on cold water. The solid product of (4) (45%) was collected after filtration with suction and recrystallized from ethanol, mp 228–231 °C. IR (KBr) ν cm–1: 2920, 2890 (CH aliphatic), 1680 (C=O), 3200 (NH). 1H NMR (DMSO-d6) δ in ppm: 2.49, 2.51, 2.86 (3s, 9H, 3CH3), 6.17 (s, 1H, Ar-H), 7.11 (s, 1H, Ar-H), 8.20 (s, 1H, Ar-H), 9.10 (br s, 1H, NH).

2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carbonitrile (5)

A mixture of ethoxymethylene cyanoactate (0.68 g, 4 mmol) and (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol (30 mL) for 8 h. The resulting precipitate was filtered off with suction, washed with ethanol, and recrystallized from ethanol to give (5) (72%), mp 220–222 °C. IR (KBr) ν cm–1: 2980, 2975 (CH aliphatic), 1665 (C=O), 2120 (C≡N), 3320–3250 (NH). 1H NMR (DMSO-d6) δ in ppm: 2.62, 2.97 (2s, 6H, 2CH3), 7.27, 7.81, 8.88 (3s, 3H, Ar-H), 9.14 (br s, 1H, NH).

2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylic Acid (6)

Acid hydrolysis occurred for (5) (0.32 g, 1 mmol) which was refluxed in 10% sulfuric acid (10 mL) for 12 h. The reaction mixture was poured on cold water, filtered off with suction, and dried to obtain a powder of (6) (41%), mp 271–273 °C. IR (KBr) ν cm–1: 3300–3200 (NH, OH), 1670 (C=O).

Ethyl 2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate (7)

A mixture of diethyl ethoxymethylenemalonate (1.3 g, 6 mmol) and (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol (30 mL) for 15 h. The resulting precipitate was filtered off with suction, washed with ethanol, and recrystallized from ethanol to give a powder of (7) (95%), mp 203–205 °C. IR (KBr) ν cm–1: 3270 (NH); 1890, 1870 (CH aliphatic), 1730, 1680 (2C=O), 1590 (C=N). 1H NMR (DMSO-d6) δ in ppm: 1.02 (t, 3H, J = 1.5 Hz, CH3CH2) 2.49, 2.58 (2s, 6H, 2CH3), 4.28 (q, 2H, J = 11 Hz, CH3CH2), 7.16 (s, 1H, Ar-H), 8.66 (s,1H, Ar-H), 9.87 (s, 1H, Ar-H).

2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-3-oxo-2,3-dihydro-1H-pyrazole-4-carbohydrazide (8)

A mixture of hydrazine hydrate (0.25 g, 5 mmol) and (7) (0.36 g, 1 mmol) was refluxed in absolute ethanol (30 mL) for 6 h. The reaction mixture was cooled, filtered off, and then dried to give a powder of (8) (53%), mp 191–193 °C. IR (KBr) ν cm–1: 3300–3200 (NH, NH2), 1670, 1663 (2C=O).

2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-N-phenylhydrazinecarbothioamide (9)

A mixture of phenyl isothiocyanate (0.54 g, 4 mmol) and (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol for 6 h. The reaction mixture was cooled and then filtered off with suction to get a solid product of (9) (58%), mp 181–183 °C. IR (KBr) ν cm–1: 3310, 3270 (NH), 1610 (C=N), 1507 (C=S). 1H NMR (DMSO-d6) δ in ppm: 2.49, 2.59 (s, 6H, 2CH3), 6.96–7.48 (m, 7H, Ar-H); 9.10 (br s, 1H, NH), 9.90 (br s, 1H, NH), 10.09 (br s, 1H, NH).

(2E)-3,4-Diphenyl-1,3-thiazol-2(3H)-one (7,9-Dimethylpyrido [3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)hydrazone (10)

A mixture of anhydrous sodium acetate (0.33 g, 4 mmol) and absolute ethanol (10 mL) was prepared to obtain (9) (0.38 g, 1 mmol), and finally phenacyl bromide (0.22 g, 1 mmol) was added. The whole mixture was refluxed for 9 h. The mixture was cooled and then filtered off with suction to get a solid product of (10) (71%), mp 207–209 °C. IR (KBr) ν cm–1: 3306 (NH), 2950, 2910 (CH aliphatic), 1600, 1580 (C=C). 1H NMR (DMSO-d6) δ in ppm: 2.43, 2.49 (2s, 6H, 2CH3), 6.68 (s, 1H, Ar-H), 6.95–8.00 (m, 12H, Ar-H).

(2E)-3-Phenyl-1,3-thiazolidine-2,4-dione 2-[(7,9-dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)hydrazone] (11)

A mixture of anhydrous sodium acetate (0.33 g, 4 mmol) and absolute ethanol (10 mL) was prepared to obtain (9) (0.38 g, 1 mmol), and finally ethylbromoacetate (0.29 g, 1 mmol) was added. The above mixture was refluxed for 9 h. The mixture was cooled and then filtered off with suction to get a solid product of (11) (71%), mp 181–183 °C. IR (KBr) ν cm–1: 3280 (NH), 2980, 2897 (CH aliphatic), 1650 (C=O), 1590 (C=N). 1H NMR (DMSO-d6) δ in ppm: 2.49, 2.52 (2s, 6H, 2CH3), 4.16 (s, 2H, CH2), 6.96–8.00 (m, 7H, Ar-H), 10.03 (br s, 1H, NH).

4-(3,5-Dimethyl-1H-pyrazol-1-yl)-7,9-dimethylpyrido[3′,2′:4,5]thieno [3,2-d]pyrimidine (12)

A mixture of acetylacetone (0.8 g, 8 mmol) and (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol (30 mL) for 7 h. The excess of ethanol was removed under reduced pressure. The resulting precipitate was filtered off with suction, washed with ethanol, and recrystallized from ethanol to give a colored powder of (12) (78%), mp 219–221 °C. IR (KBr) ν cm–1: 2950, 2980 (CH aliphatic), 1590 (C=N). 1H NMR (DMSO-d6) δ in ppm: 2.29, 2.59, 2.85, 2.91 (4s, 12H, 4CH3), 6.28 (s, 1H, Ar-H), 9.04 (s, 1H, Ar-H).

2-(7,9-Dimethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-yl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (13)

A mixture of ethylacetoacetate (0.78 g, 6 mmol) and (1) (0.98 g, 4 mmol) was refluxed in absolute ethanol (30 mL) for 9 h. The resulting precipitate was filtered off with suction, washed with ethanol, and recrystallized from ethanol to give a powder of (13) (84%), mp 237–239 °C. IR (KBr) ν cm–1: 1997, 1899 (CH aliphatic), 1670 (C=O), 1650 (C=N). 1H NMR (DMSO-d6) δ in ppm: 2.08, 2.93, 2.58 (3s, 9H, 3CH3), 3.67 (s, 2H, CH2), 7.22 (s, 1H, Ar-H), 8.67 (s, 1H, Ar-H).

Antimicrobial Screening

Preparation of the Sample

Dimethyl sulfoxide (DMSO) (12.5%) solvent was used to dissolve each of the test compounds and standards at 500 μg/mL concentration. Further diluted compounds and standards were prepared at the required quantities in the test medium.

Microorganisms’ Culture

Reference cultures of Bacillus subtilis (ATCC-6633) (Gram-positive), Pseudomonas aeruginosa (ATCC-27853) (Gram-negative), and Streptomyces species (actinomycetes) were supplied from the Microbiology Department, College of Medicine, Dar Al Uloom University, Riyadh, Kingdom of Saudi Arabia as the bacterial strains for determining antibacterial activities of the newly synthesized pyridothienopyrimidine derivatives. A Mueller–Hinton agar (MHA) medium (Oxoid Chemical Co., UK) was used to maintain the bacterial strains for 24 h at 37 °C. A formed layer of about 3–4 mm thickness was obtained by melting the medium on a water bath, inoculating with 0.5 mL of the culture of the specific microorganism and poured into sterile Petri dishes. The layer was allowed to cool and harden. With the aid of a cork-borer, cups of about 10 mm diameter were produced.25

Agar Diffusion Technique

Newly synthesized pyridothienopyrimidine derivatives were screened for their antibacterial activities against B. subtilis (Gram-positive), P. aeruginosa (Gram-negative), and Streptomyces species (actinomycetes) using MHA medium (17.5 g casein hydrolysate, 1.5 g soluble starch, and 1000 mL beef extract). A stock solution of each synthesized compound (500 μg/mL) in DMSO was prepared, and graded quantities of the test compounds were incorporated in the specified quantity of sterilized liquid MHA medium. Different concentrations of pyridothienopyrimidine derivatives in dimethylformamide were placed separately in cups in the agar medium. Overnight incubation was applied for all plates at 37 °C. The measurement of inhibition zones was performed after 24 h. The minimum inhibitory concentration (MIC) was defined as the intercept of the grave of logarithm concentrations versus diameter of the inhibition zones.26,27

The antibacterial activities of the newly synthesized pyridothienopyrimidine derivatives have been screened against three microorganisms; B. subtilis (ATCC-6633) (Gram-positive), P. aeruginosa (ATCC-27853) (Gram-negative), and Streptomyces species (actinomycetes) (Table 2).

The results of the antibacterial activities screening have shown that compounds 6, 7, 8, and 11 have the highest activity against B. subtilis with MIC values of 75 μg/mL followed by compounds 2, 3, and 4. Compound 5 has the highest inhibition power against P. aeruginosa. Among the series of screened derivatives, compounds 4, 5, 7, and 8 are the most active against Streptomyces species with MIC values of 75 μg/mL. In addition, there are compounds that have shown limited biological activities and others that have not had any antibacterial activity. The MIC values of all screened compounds are shown in Table 2.

Acknowledgments

The authors extend their appreciation to the Deanship of Post Graduate and Scientific Research at Dar Al Uloom University for funding this work.

Author Contributions

M.G.Z. and A.A.-H.A. designed and performed both the experiments and the study. Also they prepared and revised the manuscript. F.A.E.-E. designed some experiments.

The authors declare no competing financial interest.

References

  1. Katrizky A. R.Advances in Heterocyclic Chemistry; Academic Press: New York, 2007; p 132. [Google Scholar]
  2. Litvinov V. P. Thienopyrimidines: synthesis, properties, and biological activity. Russ. Chem. Bull. 2004, 53, 487–516. 10.1023/B:RUCB.0000035630.75564.2b. [DOI] [Google Scholar]
  3. Bakhite E. A.; Abdu E. A.; Elham A. A. Fluorine-containing heterocycles: Part III. Synthesis of some new furo[2,3-b]-, pyrazolo[3,4-b]- and thieno[2,3-b]pyridines with anticipated biological activities. Arabian J. Chem. 2014, 7, 936–946. 10.1016/j.arabjc.2014.05.035. [DOI] [Google Scholar]
  4. Aly H. M. Synthesis of bifunctional thieno[3,2-c]pyrazole, pyrazolothieno[2,3-d]pyrimidin derivatives and their antimicrobial activities. J. Iran. Chem. Soc. 2016, 13, 999–1009. 10.1007/s13738-016-0813-2. [DOI] [Google Scholar]
  5. Gad-Elkareem M. A. M.; Abdel-Fattah A. M.; Elneairy M. A. A. Pyridine-2(1H)-thione in heterocyclic synthesis: synthesis and antimicrobial activity of some new thio-substituted ethyl nicotinate, thieno[2,3-b]pyridine and pyridothienopyrimidine derivatives. J. Sulfur Chem. 2011, 32, 273–286. 10.1080/17415993.2011.576345. [DOI] [Google Scholar]
  6. Rateb N. M.; Abdelaziz S. H.; Zohdi H. F. Synthesis and antimicrobial evaluation of some new thienopyridine, pyrazolopyridine and pyridothienopyrimidine derivatives. J. Sulfur Chem. 2011, 32, 345–354. 10.1080/17415993.2011.593635. [DOI] [Google Scholar]
  7. Quintela J. M.; Peinador C.; González L.; Iglesias R.; Paramá A.; Álvarez F.; Sanmartín M. L.; Riguera R. Piperazine N-substituted naphthyridines, pyridothienopyrimidines and pyridothienotriazines: new antiprotozoals active against Philasterides dicentrarchi. Eur. J. Med. Chem. 2003, 38, 265–275. 10.1016/S0223-5234(03)00032-1. [DOI] [PubMed] [Google Scholar]
  8. Quintela J. M.; Peinador C.; Veiga C.; González L.; Botana L. M.; Alfonso A.; Riguera R. Synthesis and antiallergic activity of pyridothienopyrimidines. Bioorg. Med. Chem. 1998, 6, 1911–1925. 10.1016/S0968-0896(98)00150-3. [DOI] [PubMed] [Google Scholar]
  9. Sirakanyan S. N.; Akopyan E. K.; Paronikyan R. G.; Akopyan A. G.; Ovakimyan A. A. Synthesis and Anticonvulsant Activity of 7(8)-Amino Derivatives of Condensed Thieno[3,2-d]Pyrimidines. Pharm. Chem. J. 2016, 50, 296–300. 10.1007/s11094-016-1439-5. [DOI] [Google Scholar]
  10. Tolba M. S.; Ahmed M.; Kamal El-Dean A. M.; Hassanien R.; Farouk M. Synthesis of New Fused Thienopyrimidines Derivatives as Anti-inflammatory Agents. J. Heterocycl. Chem. 2018, 55, 408–418. 10.1002/jhet.3056. [DOI] [Google Scholar]
  11. Tolba M. S.; Kamal El-Dean A. M.; Ahmed M.; Hassanien R. Synthesis, reactions, and biological study of some new thienopyrimidine derivatives as antimicrobial and anti-inflammatory agents. J. Chin. Chem. Soc. 2019, 66, 548–557. 10.1002/jccs.201800292. [DOI] [Google Scholar]
  12. Shyyka O.; Pokhodylo N.; Finiuk N.; Matiychuk V.; Stoika R.; Obushak M. Anticancer Activity Evaluation of New Thieno[2,3-d]pyrimidin-4(3H)-ones and Thieno[3,2-d]pyrimidin-4(3H)-one Derivatives. Sci. Pharm. 2018, 86, 28–10. 10.3390/scipharm86030028. [DOI] [PubMed] [Google Scholar]
  13. Ghorab M.-M.; Hassan A.-Y.; Nassar O.-M. Synthesis of Novel Heterocyclic Compounds for Antitumor and Radioprotective Activities. Phosphorus, Sulfur Silicon Relat. Elem. 1998, 134, 447–462. 10.1080/10426509808545486. [DOI] [Google Scholar]
  14. Elansary A. K.; Moneer A. A.; Kadry H. H.; Gedawy E. M. Synthesis and anticancer activity of some novel fused pyridine ring system. Arch. Pharmacal Res. 2012, 35, 1909–1917. 10.1007/s12272-012-1107-6. [DOI] [PubMed] [Google Scholar]
  15. Mohamed A. T. A.; Abou-Elregal M. K.; Youssef A. S. A.; Hemdan M. M.; Samir S. S.; Abou-Elmagd W. S. I. Synthesis and antitumor activity evaluation of some thienopyrimidine derivatives. Synth. Commun. 2019, 50, 399–411. 10.1080/00397911.2019.1697822. [DOI] [Google Scholar]
  16. Fouad M. M.; El-Bendary E. R.; Suddek G. M.; Shehata I. A.; El-Kerdawy M. M. Synthesis and in vitro antitumor evaluation of some new thiophenes and thieno[2,3-d]pyrimidine derivatives. Bioorg. Chem. 2018, 81, 587–598. 10.1016/j.bioorg.2018.09.022. [DOI] [PubMed] [Google Scholar]
  17. Abbas S. E.; Abdel Gawad N. M.; George R. F.; Akar Y. A. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives. Eur. J. Med. Chem. 2013, 65, 195–204. 10.1016/j.ejmech.2013.04.055. [DOI] [PubMed] [Google Scholar]
  18. Bakhtyukov A. A.; Derkach K. V.; Dar’in D. V.; Shpakov A. O. Thienopyrimidine Derivatives Specifically Activate Testicular Steroidogenesis but Do Not Affect Thyroid Functions. J. Evol. Biochem. Physiol. 2019, 55, 30–39. 10.1134/S0022093019010046. [DOI] [Google Scholar]
  19. Jiang Y.; Zhang K.; Gao S.; Wang G.; Huang J.; Wang J.; Chen L. Discovery of Potent c-MET Inhibitors with New Scaffold Having Different Quinazoline, Pyridine and Tetrahydro-Pyridothienopyrimidine Headgroups. Molecules 2016, 21, 612–627. 10.3390/molecules21050612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. El-Nassan H. B.; Naguib B. H.; Beshay E. A. Synthesis of new pyridothienopyrimidinone and pyridothienotriazolopyrimidine derivatives as pim-1 inhibitors. J. Enzyme Inhib. Med. Chem. 2018, 33, 58–66. 10.1080/14756366.2017.1389921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yu L.; Wang Q.; Wang C.; Zhang B.; Yang Z.; Fang Y.; Zhu W.; Zheng P. Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors. Molecules 2019, 24, 3422–3435. 10.3390/molecules24193422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Abdel Aziz Y. M.; Said M. M.; El Shihawy H. A.; Abouzid K. A. M. Discovery of novel tricyclic pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors. Bioorg. Chem. 2015, 60, 1–12. 10.1016/j.bioorg.2015.03.004. [DOI] [PubMed] [Google Scholar]
  23. Abou El-Ella D. A.; Hussein M. M.; Serya R. A. T.; Abdel Naby R. M.; Al-Abd A. M.; Saleh D. O.; El-Eraky W. I.; Abouzid K. A. M. Molecular design and synthesis of 1,4-disubstituted piperazines as alpha(1)-adrenergic receptor blockers. Bioorg. Chem. 2014, 54, 21–30. 10.1016/j.bioorg.2014.03.005. [DOI] [PubMed] [Google Scholar]
  24. Wagner G.; Bohm N.; Leistner S. Synthesis of acylated 4-hydrazino-pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidines and tetracyclic compounds of the same starting tricyclic structure with a heterocyclus anellated to the pyrimidine ring. Pharmazie 1993, 48, 20–23. [Google Scholar]
  25. Jorgensen J. H.; Jurnide J. D.; Washington J. A.. Antimicrobial susceptibility tests. In Manual of Clinical Microbiology, 7th ed.; Muarry P. R., Baron E. J., Yolken R. C.; Am. Soc. Microbiol.: Washington, DC, 1999; pp 1526. [Google Scholar]
  26. Janssen A.; Scheffer J.; Svendsen A. Antimicrobial activity of essential oils: a 1976-1986 literature review. Aspects of the test methods. Planta Med. 1987, 53, 395. 10.1055/s-2006-962755. [DOI] [PubMed] [Google Scholar]
  27. Greenwood . Antimicrobial Chemotherapy, 4th ed.; Oxford University Press: New York, 2000; p 114. [Google Scholar]

Articles from ACS Omega are provided here courtesy of American Chemical Society

RESOURCES